Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2015 Healthcare Conference

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Cantor Fitzgerald Inaugural “From Bench to Bedside” Healthcare Conference on Wednesday, July 8, 2015 at 8:30a.m. ET in New York, NY. Dr. Anido’s presentation will include an Aerie overview and business update.

Dr. Anido will also participate in the “Emerging Trends in Ophthalmology: Innovative products, FDA, and the Evolving Landscape” panel at the same Cantor Fitzgerald Conference. The panel discussion will take place at 1:00p.m. ET on Wednesday, July 8, 2015.

The company presentation will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com/. A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company is currently conducting a Phase 3 registration trial in the United States named Rocket 2, where the primary efficacy endpoint is to demonstrate non-inferiority of IOP lowering for RhopressaTM compared to timolol, along with a Phase 3 registration safety-only trial, named Rocket 3, in Canada. The Company recently completed its initial Phase 3 registration trial, named Rocket 1, the three-month efficacy results of which were initially reported in April 2015, and expects to commence a fourth Phase 3 registration trial, named Rocket 4, in the third quarter of 2015. The Company also completed in 2014 a Phase 2b clinical trial in which RoclatanTM met the primary efficacy endpoint, demonstrating the statistical superiority of RoclatanTM to each of its components, and plans to commence the first Phase 3 registration trial for RoclatanTM, named Mercury 1, in the third quarter of 2015.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150701005081/en/